Effect of a perioperative digital serious game (PeroPap) on pain and anxiety in children: A randomized controlled trial.

Patient Educ CounsSep 9, 2026 (epub)
Clinical ResearchPediatricsGeneral Surgery

Dilek Küçük Alemdar, Onur Yalçın, Sevil İnal et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the PeroPap digital serious game for its effectiveness in reducing pain and anxiety in 182 children aged 7-10 undergoing surgery. Results indicated that children using PeroPap experienced significantly lower perioperative anxiety, pain, and nausea, and higher comfort levels compared to those receiving standard educational preparation.

Key findings

  • Perioperative anxiety scores were significantly higher in the control group (p < 0.001).
  • Postoperative pain scores at 1 and 2 hours after surgery were significantly higher in the control group (p < 0.001).
  • Children in the experimental group demonstrated significantly higher comfort levels than those in the control group (p < 0.001).

Why it matters

Effective management of pain and anxiety in pediatric patients is crucial for improving surgical outcomes. Digital interventions like PeroPap can enhance preoperative education, potentially leading to better patient experiences and recovery.

Source

PubMed · PMID 42753304

Published in Patient Educ Couns. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.